Price movement over the last 24 hours
AdaptHealth Corp vs Axon Enterprise Inc — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while Axon Enterprise Inc trades at $600 (market cap $51.62B). The key difference: Axon Enterprise Inc is far larger — about 37.4× AdaptHealth Corp's market cap, and Axon Enterprise Inc is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | AXON | |
|---|---|---|
Market Cap | $1.38B | $51.62B |
Sector | Health | Technology |
52-Week High | $13.38 | $870.97 |
52-Week Low | $8.68 | $345.94 |
Enterprise Value | $3.33B | $52.71B |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Axon Enterprise (AXON) trades at $622.20, up 4.21% today, with strong technical momentum as it crosses above key moving averages. The stock shows robust revenue growth, reaching $2.78 billion in 2025, though valuation ratios like a P/E of 250.95 appear elevated. Recent news highlights FAA drone defense approvals and CEO focus on non-lethal public safety technology, driving positive sentiment.
Outlook remains positive with an 80.95% analyst buy rating and $661.50 consensus price target, but risks include high valuation sensitivity and mixed earnings beats. Growth in software services and international expansion offer upside, while cash flow volatility and competitive pressures require monitoring for sustained shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →